Follow us on Twitter
twitter icon@FreshPatents


Antibodies patents

      

This page is updated frequently with new Antibodies-related patent applications.




 Diagnosis of rheumatoid arthritis patent thumbnailDiagnosis of rheumatoid arthritis
The present invention provides a method of diagnosing rheumatoid arthritis (ra), comprising: testing a sample from a subject for the presence or absence of antibodies against oxidised collagen ii; wherein the presence of antibodies against oxidised collagen ii in the sample is indicative of ra in the subject. The present invention also provides a method for identifying whether a subject responds to a disease modifying anti-rheumatic drug (dmard) and related methods of treating ra, a method for identifying whether a subject responds to an anti-tnf biologic and related methods of treating ra, and a method of diagnosing osteoarthritis (oa)..
King's Colege London


 Serological methods and diagnostic tests for syphilis antibodies patent thumbnailSerological methods and diagnostic tests for syphilis antibodies
A method of detecting antibodies to syphilis antigens includes providing a syphilis detection kit having a screening solid-phase platform with a screening portion coated with non-treponemal syphilis antigens. The screening portion is fabricated by initially dissolving cholesterol in an organic solvent and further diluting the dissolved cholesterol in an ethanol solution comprising cardiolipin and lecithin to form an antigen solution, permitting the antigen solution to evaporate at the screening portion and at least partially coating the screening portion with an antigen coating, and stabilizing the antigen coating into a syphilis antigen complex by overcoating the antigen coating with an overcoat solution comprising an inert protein..
Awareness Technology Inc.


 Method of diagnosing neoplastic conditions patent thumbnailMethod of diagnosing neoplastic conditions
The present invention relates generally to a method for detecting an aberrant cell, and more particularly an apoptotic cell, in a subject or in a biological sample from said subject, and agents useful for same. The presence of the aberrant cell or group of aberrant cells provides an indication of a particular disease or condition or a propensity for development of a disease or condition.
Medvet Science Pty Ltd


 In situ affinity maturation of antibodies patent thumbnailIn situ affinity maturation of antibodies
This disclosure relates to a method to mimicking the germinal center reaction to generate antibodies with altered binding properties or increased affinity directly in hybridomas. To allow convenient and rapid affinity maturation of antibodies, a controllable activation-induced cytidine deaminase (aid) expression system to induce somatic hypermutation in hybridomas is developed.
Academia Sinica


 Cell-free biofragment compositions and related systems, devices, and methods patent thumbnailCell-free biofragment compositions and related systems, devices, and methods
The present disclosure relates to biofragment compositions that comprise bioparticle fragments and at least one heterologous antigen-binding molecule. In some embodiments, the biofragment is typically derived from a larger, intact bioparticle that express the at least one heterologous antigen-binding molecule at the surface, and the biofragment has increased solubility to facilitate assays for antigen detection.
The University Of Queensland


 Peptoids that bind specific antigens patent thumbnailPeptoids that bind specific antigens
Combinatorial libraries were generated providing a vast number of diverse peptoid ligands. From these libraries, ligands were identified which specifically bind molecules associated with autoimmune diseases, such as antibodies specific to aquaporin-4 (aqp4), binding of which to aqp4 causes the autoimmune disease, neuoromyelitis optica.
The Scripps Research Institute


 Solid phase labeling method patent thumbnailSolid phase labeling method
The invention provides for the labeling of antibodies with a fluorescent label, using a solid support comprising an affinity for an fc portion of an antibody. Thus, the invention provides a method for labeling an antibody or fragment thereof with a fluorescent label, comprising the steps of immobilizing an antibody on the solid support and covalently coupling a fluorescent label to the immobilized antibody, as well as a kit for performing such method..
Mu Bioteknik Ab


 Compositions and methods for detecting human pegivirus 2 (hpgv-2) patent thumbnailCompositions and methods for detecting human pegivirus 2 (hpgv-2)
Provided herein are compositions, methods, and kits for detecting human pegivirus 2 (hpgv-2). In certain embodiments, provided herein are hpgv-2 specific nucleic acid probes and primers, and methods for detecting hpgv-2 nucleic acid.
The Regents Of The University Of California


 Humanized anti-factor d antibodies and uses thereof patent thumbnailHumanized anti-factor d antibodies and uses thereof
The invention relates to humanized anti-human factor d monoclonal antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease..
Genentech, Inc.


 Anti-pad2 antibodies and treatment of autoimmune diseases patent thumbnailAnti-pad2 antibodies and treatment of autoimmune diseases
The present invention relates to anti-peptidylarginine deiminase 2 (pad2) antibodies and anti-pad2 antibodies for use in the treatment of autoimmune diseases characterized by extracellular citrullination, such as rheumatoid arthritis (ra). The invention further relates to a method for treatment of an autoimmune disease characterized by extracellular citrullination comprising the administration of a suitable amount of an anti-pad2 antibody to a subject..
Rigshospitalet


Methods of producing antibodies specific for p95

The invention provides methods of measuring and/or quantifying the presence and/or amount of p95 and/or p95 complex in a sample. The invention also provides antibodies specific for p95, and methods of making such antibodies..
Laboratory Corporation Of America Holdings

Anti c-met antibodies

The present invention relates to antibodies that specifically bind to the human c-met receptor protein and that act as strict antagonists of hepatocyte growth factor (hgf)-mediated activation of the c-met receptor and also inhibit hgf-independent activation of the human c-met protein.. .
Argen-x N.v.

Anti c-met antibodies

The present invention relates to antibodies that specifically bind to the human c-met receptor protein and that act as strict antagonists of hepatocyte growth factor (hgf)-mediated activation of the c-met receptor and also inhibit hgf-independent activation of the human c-met protein.. .
Argen-x N.v.

Antibodies specific for cll-1

Provided herein are antibodies specific for cll-1.. .
Cellerant Therapeutics, Inc.

Bispecific antibodies against cd3 and bcma

A bispecific antibody specifically binding to the two targets human cd3ε and human bcma, wherein the variable domains of one antibody portion are replaced by each other, and characterized in that the binding of said antibody is not reduced by april and not reduced by baff, said antibody does not alter april-dependent nf-κb activation, baff-dependent nf-κb activation, and does not alter nf-κb activation without baff and april is useful as a therapeutic agent.. .
Engmab Ag

Antibodies against epidermal growth factor receptor (egfr) and uses thereof

Anti-egfr antibodies, therapeutic compositions comprising combinations of anti-egfr antibodies, as well as methods for using such antibodies and compositions to treat egfr-related disorders (e.g., cancers), are disclosed.. .
Adimab, Llc

Fgfr1 agonists and methods of use

The invention provides fgfr1 agonists, including agonistic anti-fgfr1 antibodies, and methods of using the same.. .
Genentech, Inc.

Antibody variants having modifications in the constant region

The present invention relates to positions in the constant region of antibodies, in particular the ch3 region of igg4, which affect the strength of ch3-ch3 interactions. Mutations that either stabilize or destabilize this interaction are disclosed..
Genmab A/s

Cell penetrating nucleolytic antibody based cancer therapy

Cancer cells with defects in dna repair are highly susceptible to dna-damaging agents, but delivery of therapeutic agents into cell nuclei can be challenging. A sub-set of autoantibodies having nucleolytic activity are capable of nuclear penetration.
The United States Government As Represented By The Department Of Veteran Affairs

Anti-cd83 antibodies and use thereof

The present disclosure relates to proteins that bind to cd83 and uses thereof, for example, in therapy, prophylaxis, diagnosis, or prognosis.. .
The Regents Of The University Of California

Anti-ntb-a antibodies and related compositions and methods

Disclosed are antibodies, including antibody drug conjugates, that specifically bind to ntb-a. Also disclosed are methods for using the anti-ntb-a antibodies to detect or modulate activity of (e.g., inhibit proliferation of) an ntb-a-expressing cell, as well as for diagnoses or treatment of diseases or disorders (e.g., cancer) associated with ntb-a-expressing cells.
Seattle Genetics, Inc.

Anti-kir antibodies for the treatment of inflammatory and autoimmune disorders

This invention relates to compounds that inhibit kir2dl1, 2 and/or 3 polypeptide comprising compounds (e.g., anti-kir2dl1, 2, and/or 3 antibodies) that neutralize nk cell inhibitory receptors and methods of using such compounds and compositions containing in the treatment and prevention of inflammatory or autoimmune disorders.. .
Innate Pharma, Sa

Treatment of peripheral t cell lymphoma

The present disclosure relates to methods for the treatment, prevention and diagnostic of peripheral t cell lymphoma using compounds that specifically bind nkp46. Included in particular are compounds that bind nkp46 and deplete tumor cells that express at their surface nkp46, and pharmaceutical compositions comprising the same.
Innate Pharma

Antibodies to ntb-a

Anti-ntb-a antibodies and antigen-binding fragments thereof, as well as pharmaceutical compositions comprising such antibodies and antigen-binding fragments are described. Also described are methods of using such antibodies and antigen-binding regions to bind ntb-a and treat diseases, such as hematologic malignancies, which are characterized by expression of ntb-a..
Arca Biopharma, Inc.

Inhibition of angiogenesis in refractory tumors

The present invention relates generally to the inhibition of tumor angiogenesis. In particular, the invention concerns the prevention or treatment of tumor angiogenesis and the suppression of tumor growth in tumors refractory to an anti-vascular endothelial growth factor (vegf) treatment, using il-17 antagonists, such as anti-il-17 antibodies and other antagonists..
Genentech, Inc.

Human antibodies to serum resistance-associated protein from trypanosoma brucei rhodesiense

The present invention provides antibodies that bind to serum resistance-associated (sra) protein of trypanosoma brucei rhodesiense, and methods of use. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to sra.
Regeneron Pharmaceuticals, Inc.

Antibodies to oxidized phospholipids

The disclosure provides for single chain variable fragments to oxidized phospholipid epitopes and methods of use thereof, including the production of transgenic animal models and the use of the fragments as therapeutic agents for treating cas.. .
The Regents Of The University Of California

Human antibodies to human delta like ligand 4

The present invention provides methods of treating, ameliorating, or inhibiting tumor growth, cancer, or pathological angiogenesis by administering to a subject in need thereof a human antibody or fragment thereof that specifically binds to human delta-like ligand 4 (hdll4) and blocks hdll4 binding to a notch receptor. The anti-hdll4 antibody or fragment thereof of the present invention have a high affinity with the kd of 500 pm or less, as measured by surface plasmon resonance..
Regeneron Pharmaceuticals, Inc.

Antibody compositions and methods of use

The invention provides compositions comprising anti-gh antibodies and anti-complex i antibodies as well as methods of using the same.. .
Genentech, Inc.

Bovine fusion antibodies

Disclosed herein are immunoglobulin constructs comprising at least one immunoglobulin domain or fragment thereof; and a therapeutic polypeptide or derivative or variant thereof attached to or inserted into said immunoglobulin domain. Also provided are immunoglobulin constructs comprising a mammalian immunoglobulin heavy chain comprising at least a portion of a knob domain in the complementarity-determining region 3 (cdr3h) or fragment thereof; and a therapeutic polypeptide attached to or inserted into the cdr3h.
The California Institute For Biomedical Research

Axmi115 variant insecticidal gene and methods for its use

Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. The toxin coding sequences can be used in dna constructs or expression cassettes for expression in plants and bacteria.
Athenix Corp.

Methods for the treatment of head and neck squamous cell carcinoma

This invention relates to the staging, diagnosis, and treatment of cancerous diseases, particularly to the use of monoclonal antibodies, antigen binding fragments thereof, and/or cancerous disease modifying antibodies (cdmab), optionally in combination with one or more cdmab, chemotherapeutic agents, and conjugates thereof, as a means for initiating a cytotoxic response to human head and neck squamous cell carcinomas. The invention further relates to binding assays, which utilize the monoclonal antibodies, antigen binding fragments thereof, and/or cdmab of the instant invention.
University Of Miami

Anti-pmel17 antibodies and immunoconjugates

The invention provides anti-pmel17 antibodies and immunoconjugates and methods of using the same.. .
Genentech, Inc.

Combination therapy involving antibodies against claudin 18.2 for treatment of cancer

The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing cldn18.2, including cancer diseases such as pancreatic cancer and metastases thereof.. .
Tron-translationale Onkologie An Der Universitats- Medizin Der Johannes Gutenberg-universitat Mainz.

Zhankuic acid a and analogs thereof and their use as an anti-inflammatory agent

Zhankuic acid a (zaa) is the major pharmacologically active compound of taiwanofungus camphoratus. We analyzed the structure of human tlr4/md-2 complex with zaa by x-score and hotlig modeling approaches.
National Cheng Kung University

Methods for treating and diagnosing systemic lupus erythematosus

Methods and reagents for diagnosing, prognosing, and treating systemic lupus erythematosus (sle) are disclosed, involving calculating an sle risk score for a subject based on a level of each of an erythrocyte c4d (ec4d) marker, a b-cell c4d (bc4d) marker, antinuclear antibodies (ana), anti-smith antibodies (anti-sm) and optional rule-out markers (ss-b/la, scl-70, jo-1, cenp, mcv).. .
Exagen Diagnostics, Inc.

Methods for generating stabilized lyophilized materials

Lyophilized biological reagents, such as enzymes (e.g., pcr reagents) and antibodies, are provided that include a wax component. Thus, in some aspects, a method is provided for storing a biological reagent comprising formulating the reagent into a lyophilized composition including a wax component.
Luminex Corporation

Methods for producing antibodies

Methods for producing antibodies are provided and include transforming a plant cell with a nucleic acid encoding a heavy chain of an antibody, a light chain of an antibody, and a linking polypeptide connecting the heavy chain to the light chain. The nucleic acid is then expressed in the plant cell, such that, upon expression the linking polypeptide is cleaved to separate the heavy chain from the light chain.
University Of Louisville Research Foundation, Inc.

Use of human cells of myeloid leukaemia origin for expression of antibodies

The invention relates to a method for producing a protein molecule composition having a defined glycosylation pattern, comprising (a) introducing in a host cell which is an immortalized human blood cell at least one nucleic acid encoding at least a part of said protein; and (b) culturing said host cell under conditions which permit the production of said protein molecule composition; and (c) isolating said protein molecule composition.. .
Glycotope Gmbh

Antibodies against epidermal growth factor receptor (egfr) and uses thereof

Anti-egfr antibodies, therapeutic compositions comprising combinations of anti-egfr antibodies, as well as methods for using such antibodies and compositions to treat egfr-related disorders (e.g., cancers), are disclosed.. .
Adimab, Llc

Highly galactosylated anti-her2 antibodies and uses thereof

In one aspect, the disclosure relates to highly galactosylated anti-her2 antibodies and compositions thereof. In one aspect, the disclosure relates to populations of anti-her2 antibodies with a high level of galactosylation, and compositions thereof.
Laboratoire Francais Du Fractionnement Et Des Biotechnologies

Tumor specific antibodies and uses therefor

Provided are isolated antibodies, and fragments and derivatives thereof, which bind to tumor antigens. Also provided are compositions and delivery agents that include the disclosed antibodies and fragments and derivatives thereof; cells that produce the same; methods for producing the same; methods of using the same for detecting, targeting, and/or treating tumors and/or metastatic cells derived therefrom and/or tumor stem cells; and methods for predicting the recurrence of cancer in a subject..
Unc-charlotte

Anti-podoplanin antibodies and methods of use

Recombinant scfv-immunotoxins target tumor cells expressing human podoplanin but not podoplanin-negative or normal cells. The immunotoxins can be used for treatment of malignant glioma patients or any malignant tumor expressing podoplanin.
The Government Of The United States As Represented By The Secretary, Department Of Health & Human

Novel multispecific constructs

Provided are novel multispecific antibody constructs and multispecific antibody drug conjugates (adcs), and methods of using such antibodies and adcs to treat cancer. Igg-like bispecific antibodies have different binding specificities on each arm of the antibody.
Stemcentrx, Inc.

Method for the selection of antibodies against bcma

An antibody specifically binding to human bcma, characterized in that the binding of said antibody is not reduced by april and not reduced by baff, said antibody does not alter april-dependent nf-κb activation, baff-dependent nf-κb activation, and does not alter nf-κb activation without baff and april is useful as a therapeutic agent.. .
Engmab Ag

Anti-gitr antibodies and methods of use thereof

The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced tnfr family related receptor (gitr) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human gitr and modulate gitr activity, e.g., enhance, activate or induce gitr activity, utilizing such antibodies.
4-antibody Ag

Antibodies against epidermal growth factor receptor (egfr) and uses thereof

Anti-egfr antibodies, therapeutic compositions comprising combinations of anti-egfr antibodies, as well as methods for using such antibodies and compositions to treat egfr-related disorders (e.g., cancers), are disclosed.. .
Adimab, Llc

Antibodies against epidermal growth factor receptor (egfr) and uses thereof

Anti-egfr antibodies, therapeutic compositions comprising combinations of anti-egfr antibodies, as well as methods for using such antibodies and compositions to treat egfr-related disorders (e.g., cancers), are disclosed.. .
Adimab, Llc

Antibody variants having modifications in the constant region

The present invention relates to positions in the constant region of antibodies, in particular the ch3 region of lgg4, which affect the strength of ch3-ch3 interactions. Mutations that either stabilize or destabilize this interaction are disclosed..
Genmab A/s

Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof

Small animal models for assessing immunomodulatory effects of compounds are provided.. .
Alexion Pharmaceuticals, Inc.

Human monoclonal antibodies specific for glypican-3 and use thereof

Described herein is the identification of human monoclonal antibodies that bind gpc3 or heparan sulfate (hs) chains on gpc3 with high affinity. The antibodies described herein are capable of inhibiting hcc cell growth and migration.

Interferon alpha and omega antibody antagonists

The present invention relates to antibodies that broady neutralize interferon-α and interferon-ω, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.. .
Janssen Biotech, Inc.

Anti-il-6 antibodies for the treatment of oral mucositis

The present invention is directed to therapeutic methods using il-6 antagonists such as anti-il-6 antibodies and fragments thereof having binding specificity for il-6 to prevent or treat mucositis (e.g., oral mucositis) including persons on a treatment regimen with a drug or chemotherapy and/or radiation for cancer (e.g., head and neck cancer) that is associated with increased risk of mucositis, including oral mucositis.. .
Alderbio Holdings Llc

Il-31 monoclonal antibodies

The present invention relates to methods of treating pruritic diseases, including but not limited to contact dermatitis, atopic dermatitis, drug induced delayed type cutaneous allergic reactions, toxic epidermal necrolysis, cutaneous t cell lymphoma, bullous pemphigoid, alopecia wereata, vitiligo, acne rosacea, prurigo nodularis, scleroderma, herpes simplex virus, or combination thereof by administering il-31 monoclonal antibodies. The invention further provides the hybridomas that generate the monoclonal antibodies..
Zymogenetics, Inc.

Treatment of tnf-alpha related disorders

Methods of treating tnfα-related disorders comprising administering tnfα inhibitors, including tnfα antibodies are described.. .
Abbott Biotechnology Ltd.

Highly galactosylated anti-tnf-alpha antibodies and uses thereof

In one aspect, the disclosure relates to highly galactosylated anti-tnf-alpha antibodies and compositions thereof. In one aspect, the disclosure relates to populations of anti-tnf-alpha antibodies with a high level of galactosylation, and compositions thereof.
Laboratoire FranÇais Du Fractionnement Et Des Biotechnologies

Tnf-alpha antigen-binding proteins

The present invention provides antigen binding proteins which bind specifically to tnf-alpha. For example novel variants of anti-tnf antibodies such as adalimumab which show increased binding to the fcrn receptor or increased half life compared to adalimumab.
Glaxosmithkline Intellectual Property Development Limited

Angiopoietin-related protein 4 (cangptl4) as a diagnostic biomarker for acute lung damage

The invention relates to the c-terminal fragment of angiopoietin-related protein 4 [cangptl4] as a diagnostic marker for viral and bacterial pneumonia; anti-angiopoietin-related protein 4 therapeutic antibodies, and the use of anti-angiopoietin-related protein 4 antibodies in the treatment of viral and bacterial pneumonia.. .
National University Of Singapore

Methods of preventing or treating pain using anti-ngf antibodies that selectively inhibit the association of ngf with trka, without affecting the association of ngf with p75

This invention pertains to ngf antagonists including antibodies and antibody fragments thereof having binding specificity to human nerve growth factor (“ngf”), and methods of treating pain. Methods of treating pain or eliciting an analgesic effect in an individual comprising administering an effective amount of an ngf antagonist inhibits the association of ngf with trka without inhibiting the association of ngf with p75.
Alderbio Holdings Llc

Methods of treating ocular diseases

The present invention relates to vegf-binding agents, dll4-binding agents, vegf/dll4 bispecific binding agents, and methods of using the agents for treating ocular diseases. The present invention provides antibodies that specifically bind human vegf, antibodies that specifically bind human dll4, and bispecific antibodies that specifically bind human vegf and/or human dll4.
Oncomed Pharmaceuticals, Inc.

Immunotherapy for clearing pathological tau conformers

The present invention relates to methods of treating and preventing alzheimer's disease or other tauopathies in a subject by administering a tau protein, its immunogenic epitopes, or antibodies recognizing the tau protein or its immunogenic epitopes under conditions effective to treat or prevent alzheimer's disease of other tauopathies. Also disclosed are methods of promoting clearance of from the brain of the subject and of slowing progression of tangle-related behavioral phenotype in a subject..
New York University

Anti-staphylococcal antibodies

This disclosure generally relates to antibodies or fragments thereof which interact with the bacterial protein mprf. The disclosure further discloses antibodies, which bind to specific extracellular motifs of mprf.
Morphosys Ag

Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease

Embodiments concern methods and compositions for treating or preventing a bacterial infection, particularly infection by a staphylococcus bacterium. Aspects include methods and compositions for providing a passive immune response against the bacteria, in certain embodiments, the methods and compositions involve an antibody that binds coagulase (coa)..

Novel full spectrum anti-dengue antibody

The present invention provides, among other things, antibody agents (e.g., antibodies, and/or antigen-binding fragments thereof) that bind to dv epitopes, as well as compositions containing them and methods of designing, providing, formulating, using, identifying and/or characterizing them. In some embodiments, provided antibody agents show significant binding to a plurality of dv serotypes.
Massachusetts Institute Of Technology

Polyclonal antibodies against clostridium difficile and uses thereof

A polyclonal antibody composition prepared from eggs of immunized hens is used to treat c. Difficile infections.
Immunimed Inc.

Axmi218, axmi219, axmi220, axmi226, axmi227, axmi228, axmi229, axmi230 and axmi231 delta-endotoxin genes and methods for their use

Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for a toxin polypeptide are provided.
Athenix Corp.

Amyloid-beta binding proteins

The present invention relates to amyloid-beta (aβ) binding proteins. antibodies of the invention have high affinity to aβ(20-42) globulomer or any β form that comprises the globulomer epitope.
Abbvie Inc.



Antibodies topics:
  • Antibodies
  • Recombinant
  • Nucleic Acid
  • Nucleic Acids
  • Polypeptide
  • Therapeutics
  • Immunoglobulin
  • Immunoglobulins
  • Monoclonal
  • Radiation Therapy
  • Desmoplastic
  • Hypertension
  • Hypertensive
  • Immunotherapy
  • Photodynamic Therapy


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Antibodies for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Antibodies with additional patents listed. Browse our RSS directory or Search for other possible listings.


    2.4352

    file did exist - 3350

    1 - 1 - 72